| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Doxylamine/pyridoxine |
| Brand | Xonvea® |
| Indication | For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. |
| Assessment Process | |
| Rapid review commissioned | 23/07/2019 |
| Rapid review completed | 15/08/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Xonvea®) not be considered for reimbursement at the submitted price* |
* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.